Exact Sciences Corporation
Exact Sciences Corporation (EXAS) Stock Competitors & Peer Comparison
See (EXAS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EXAS | $104.91 | +0.00% | 20B | -95.37 | -$1.10 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.84% |
| TMO | $438.34 | -2.20% | 162.8B | 24.08 | $18.20 | +0.40% |
| DHR | $161.91 | -1.60% | 114.6B | 31.38 | $5.16 | +0.84% |
| IDXX | $528.79 | -0.76% | 41.7B | 38.91 | $13.59 | N/A |
| A | $111.70 | -1.38% | 31.6B | 24.65 | $4.53 | +0.67% |
| IQV | $169.12 | -0.91% | 28.2B | 20.98 | $8.06 | N/A |
| NTRA | $186.36 | -5.36% | 26.7B | -115.01 | -$1.62 | N/A |
| ILMN | $142.54 | -0.49% | 21.6B | 25.92 | $5.50 | N/A |
| WAT | $329.22 | -1.20% | 21.5B | 41.88 | $7.86 | N/A |
Stock Comparison
EXAS vs DHR-PB Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, EXAS is priced at $104.91, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, EXAS's ROE is -0.09%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, EXAS is less volatile compared to DHR-PB. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check DHR-PB's competition here
EXAS vs TMO Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, TMO has a market cap of 162.8B. Regarding current trading prices, EXAS is priced at $104.91, while TMO trades at $438.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas TMO's P/E ratio is 24.08. In terms of profitability, EXAS's ROE is -0.09%, compared to TMO's ROE of +0.13%. Regarding short-term risk, EXAS is less volatile compared to TMO. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check TMO's competition here
EXAS vs DHR Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, DHR has a market cap of 114.6B. Regarding current trading prices, EXAS is priced at $104.91, while DHR trades at $161.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas DHR's P/E ratio is 31.38. In terms of profitability, EXAS's ROE is -0.09%, compared to DHR's ROE of +0.07%. Regarding short-term risk, EXAS is less volatile compared to DHR. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check DHR's competition here
EXAS vs IDXX Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, IDXX has a market cap of 41.7B. Regarding current trading prices, EXAS is priced at $104.91, while IDXX trades at $528.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas IDXX's P/E ratio is 38.91. In terms of profitability, EXAS's ROE is -0.09%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, EXAS is less volatile compared to IDXX. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check IDXX's competition here
EXAS vs A Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, A has a market cap of 31.6B. Regarding current trading prices, EXAS is priced at $104.91, while A trades at $111.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas A's P/E ratio is 24.65. In terms of profitability, EXAS's ROE is -0.09%, compared to A's ROE of +0.20%. Regarding short-term risk, EXAS is less volatile compared to A. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check A's competition here
EXAS vs IQV Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, IQV has a market cap of 28.2B. Regarding current trading prices, EXAS is priced at $104.91, while IQV trades at $169.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas IQV's P/E ratio is 20.98. In terms of profitability, EXAS's ROE is -0.09%, compared to IQV's ROE of +0.22%. Regarding short-term risk, EXAS is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check IQV's competition here
EXAS vs NTRA Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, NTRA has a market cap of 26.7B. Regarding current trading prices, EXAS is priced at $104.91, while NTRA trades at $186.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas NTRA's P/E ratio is -115.01. In terms of profitability, EXAS's ROE is -0.09%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, EXAS is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check NTRA's competition here
EXAS vs ILMN Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, ILMN has a market cap of 21.6B. Regarding current trading prices, EXAS is priced at $104.91, while ILMN trades at $142.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas ILMN's P/E ratio is 25.92. In terms of profitability, EXAS's ROE is -0.09%, compared to ILMN's ROE of +0.34%. Regarding short-term risk, EXAS is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check ILMN's competition here
EXAS vs WAT Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, WAT has a market cap of 21.5B. Regarding current trading prices, EXAS is priced at $104.91, while WAT trades at $329.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas WAT's P/E ratio is 41.88. In terms of profitability, EXAS's ROE is -0.09%, compared to WAT's ROE of +0.08%. Regarding short-term risk, EXAS is less volatile compared to WAT. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check WAT's competition here
EXAS vs MTD Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, MTD has a market cap of 20.9B. Regarding current trading prices, EXAS is priced at $104.91, while MTD trades at $1,031.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas MTD's P/E ratio is 23.87. In terms of profitability, EXAS's ROE is -0.09%, compared to MTD's ROE of -6.10%. Regarding short-term risk, EXAS is less volatile compared to MTD. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check MTD's competition here
EXAS vs DGX Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, DGX has a market cap of 20.7B. Regarding current trading prices, EXAS is priced at $104.91, while DGX trades at $186.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas DGX's P/E ratio is 20.62. In terms of profitability, EXAS's ROE is -0.09%, compared to DGX's ROE of +0.14%. Regarding short-term risk, EXAS is less volatile compared to DGX. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check DGX's competition here
EXAS vs LH Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, LH has a market cap of 20.5B. Regarding current trading prices, EXAS is priced at $104.91, while LH trades at $250.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas LH's P/E ratio is 22.15. In terms of profitability, EXAS's ROE is -0.09%, compared to LH's ROE of +0.11%. Regarding short-term risk, EXAS is less volatile compared to LH. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check LH's competition here
EXAS vs PKI Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, EXAS is priced at $104.91, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas PKI's P/E ratio is 41.45. In terms of profitability, EXAS's ROE is -0.09%, compared to PKI's ROE of +0.03%. Regarding short-term risk, EXAS is less volatile compared to PKI. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check PKI's competition here
EXAS vs GH Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, GH has a market cap of 12.6B. Regarding current trading prices, EXAS is priced at $104.91, while GH trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas GH's P/E ratio is -27.92. In terms of profitability, EXAS's ROE is -0.09%, compared to GH's ROE of +1.84%. Regarding short-term risk, EXAS is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check GH's competition here
EXAS vs MEDP Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, MEDP has a market cap of 11.9B. Regarding current trading prices, EXAS is priced at $104.91, while MEDP trades at $415.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas MEDP's P/E ratio is 26.13. In terms of profitability, EXAS's ROE is -0.09%, compared to MEDP's ROE of +1.21%. Regarding short-term risk, EXAS is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check MEDP's competition here
EXAS vs RVTY Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, RVTY has a market cap of 10.5B. Regarding current trading prices, EXAS is priced at $104.91, while RVTY trades at $93.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas RVTY's P/E ratio is 45.20. In terms of profitability, EXAS's ROE is -0.09%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, EXAS is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check RVTY's competition here
EXAS vs ICLR Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, ICLR has a market cap of 8.9B. Regarding current trading prices, EXAS is priced at $104.91, while ICLR trades at $116.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas ICLR's P/E ratio is 15.68. In terms of profitability, EXAS's ROE is -0.09%, compared to ICLR's ROE of +0.06%. Regarding short-term risk, EXAS is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check ICLR's competition here
EXAS vs CRL Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CRL has a market cap of 7.3B. Regarding current trading prices, EXAS is priced at $104.91, while CRL trades at $150.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CRL's P/E ratio is -40.66. In terms of profitability, EXAS's ROE is -0.09%, compared to CRL's ROE of -0.06%. Regarding short-term risk, EXAS is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check CRL's competition here
EXAS vs QGEN Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, QGEN has a market cap of 6.8B. Regarding current trading prices, EXAS is priced at $104.91, while QGEN trades at $32.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas QGEN's P/E ratio is 16.83. In terms of profitability, EXAS's ROE is -0.09%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, EXAS is less volatile compared to QGEN. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check QGEN's competition here
EXAS vs SYNH Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, EXAS is priced at $104.91, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas SYNH's P/E ratio is 61.40. In terms of profitability, EXAS's ROE is -0.09%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, EXAS is less volatile compared to SYNH. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check SYNH's competition here
EXAS vs SHC Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, SHC has a market cap of 4.4B. Regarding current trading prices, EXAS is priced at $104.91, while SHC trades at $15.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas SHC's P/E ratio is 37.24. In terms of profitability, EXAS's ROE is -0.09%, compared to SHC's ROE of +0.21%. Regarding short-term risk, EXAS is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check SHC's competition here
EXAS vs RDNT Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, RDNT has a market cap of 4.1B. Regarding current trading prices, EXAS is priced at $104.91, while RDNT trades at $52.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas RDNT's P/E ratio is -308.18. In terms of profitability, EXAS's ROE is -0.09%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, EXAS is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check RDNT's competition here
EXAS vs BLLN Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BLLN has a market cap of 3.8B. Regarding current trading prices, EXAS is priced at $104.91, while BLLN trades at $82.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BLLN's P/E ratio is 158.90. In terms of profitability, EXAS's ROE is -0.09%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, EXAS is less volatile compared to BLLN. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check BLLN's competition here
EXAS vs OLK Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, EXAS is priced at $104.91, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas OLK's P/E ratio is -96.59. In terms of profitability, EXAS's ROE is -0.09%, compared to OLK's ROE of -0.07%. Regarding short-term risk, EXAS is less volatile compared to OLK. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check OLK's competition here
EXAS vs TWST Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, TWST has a market cap of 3.1B. Regarding current trading prices, EXAS is priced at $104.91, while TWST trades at $49.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas TWST's P/E ratio is -37.25. In terms of profitability, EXAS's ROE is -0.09%, compared to TWST's ROE of -0.17%. Regarding short-term risk, EXAS is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check TWST's competition here
EXAS vs GRAL Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, GRAL has a market cap of 2.6B. Regarding current trading prices, EXAS is priced at $104.91, while GRAL trades at $59.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas GRAL's P/E ratio is -5.79. In terms of profitability, EXAS's ROE is -0.09%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, EXAS is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check GRAL's competition here
EXAS vs NEOG Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, NEOG has a market cap of 1.8B. Regarding current trading prices, EXAS is priced at $104.91, while NEOG trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas NEOG's P/E ratio is -2.89. In terms of profitability, EXAS's ROE is -0.09%, compared to NEOG's ROE of -0.29%. Regarding short-term risk, EXAS is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check NEOG's competition here
EXAS vs CDNA Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CDNA has a market cap of 1B. Regarding current trading prices, EXAS is priced at $104.91, while CDNA trades at $19.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CDNA's P/E ratio is -124.81. In terms of profitability, EXAS's ROE is -0.09%, compared to CDNA's ROE of -0.03%. Regarding short-term risk, EXAS is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check CDNA's competition here
EXAS vs CSTL Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CSTL has a market cap of 580.2M. Regarding current trading prices, EXAS is priced at $104.91, while CSTL trades at $19.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CSTL's P/E ratio is -45.55. In terms of profitability, EXAS's ROE is -0.09%, compared to CSTL's ROE of -0.03%. Regarding short-term risk, EXAS is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check CSTL's competition here
EXAS vs GRALV Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, EXAS is priced at $104.91, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas GRALV's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to GRALV's ROE of N/A. Regarding short-term risk, EXAS is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check GRALV's competition here
EXAS vs PSNL Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, PSNL has a market cap of 564.8M. Regarding current trading prices, EXAS is priced at $104.91, while PSNL trades at $6.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas PSNL's P/E ratio is -6.24. In terms of profitability, EXAS's ROE is -0.09%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, EXAS is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check PSNL's competition here
EXAS vs FLGT Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, FLGT has a market cap of 445.9M. Regarding current trading prices, EXAS is priced at $104.91, while FLGT trades at $15.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas FLGT's P/E ratio is -6.54. In terms of profitability, EXAS's ROE is -0.09%, compared to FLGT's ROE of -0.07%. Regarding short-term risk, EXAS is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check FLGT's competition here
EXAS vs CO Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, EXAS is priced at $104.91, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CO's P/E ratio is 5.06. In terms of profitability, EXAS's ROE is -0.09%, compared to CO's ROE of +0.11%. Regarding short-term risk, EXAS is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check CO's competition here
EXAS vs MYGN Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, MYGN has a market cap of 338.1M. Regarding current trading prices, EXAS is priced at $104.91, while MYGN trades at $3.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas MYGN's P/E ratio is -0.83. In terms of profitability, EXAS's ROE is -0.09%, compared to MYGN's ROE of -1.09%. Regarding short-term risk, EXAS is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check MYGN's competition here
EXAS vs FLDM Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, EXAS is priced at $104.91, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas FLDM's P/E ratio is -4.74. In terms of profitability, EXAS's ROE is -0.09%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, EXAS is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check FLDM's competition here
EXAS vs OPGN Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, OPGN has a market cap of 242.7M. Regarding current trading prices, EXAS is priced at $104.91, while OPGN trades at $23.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas OPGN's P/E ratio is 132.83. In terms of profitability, EXAS's ROE is -0.09%, compared to OPGN's ROE of +0.78%. Regarding short-term risk, EXAS and OPGN have similar daily volatility (0.00).Check OPGN's competition here
EXAS vs PRE Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, PRE has a market cap of 219.4M. Regarding current trading prices, EXAS is priced at $104.91, while PRE trades at $15.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas PRE's P/E ratio is -6.35. In terms of profitability, EXAS's ROE is -0.09%, compared to PRE's ROE of -0.36%. Regarding short-term risk, EXAS is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check PRE's competition here
EXAS vs NEO Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, NEO has a market cap of 214.6M. Regarding current trading prices, EXAS is priced at $104.91, while NEO trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas NEO's P/E ratio is -10.70. In terms of profitability, EXAS's ROE is -0.09%, compared to NEO's ROE of -0.12%. Regarding short-term risk, EXAS is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check NEO's competition here
EXAS vs IMDX Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, IMDX has a market cap of 172.1M. Regarding current trading prices, EXAS is priced at $104.91, while IMDX trades at $6.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas IMDX's P/E ratio is -4.25. In terms of profitability, EXAS's ROE is -0.09%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, EXAS is less volatile compared to IMDX. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check IMDX's competition here
EXAS vs GTH Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, EXAS is priced at $104.91, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas GTH's P/E ratio is -1.11. In terms of profitability, EXAS's ROE is -0.09%, compared to GTH's ROE of -1.01%. Regarding short-term risk, EXAS is less volatile compared to GTH. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check GTH's competition here
EXAS vs ATLN Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, ATLN has a market cap of 112.7M. Regarding current trading prices, EXAS is priced at $104.91, while ATLN trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas ATLN's P/E ratio is -1.31. In terms of profitability, EXAS's ROE is -0.09%, compared to ATLN's ROE of +2.74%. Regarding short-term risk, EXAS is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check ATLN's competition here
EXAS vs GENE Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, EXAS is priced at $104.91, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas GENE's P/E ratio is -38.25. In terms of profitability, EXAS's ROE is -0.09%, compared to GENE's ROE of -1.85%. Regarding short-term risk, EXAS and GENE have similar daily volatility (0.00).Check GENE's competition here
EXAS vs BDSX Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BDSX has a market cap of 108.7M. Regarding current trading prices, EXAS is priced at $104.91, while BDSX trades at $14.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BDSX's P/E ratio is -3.64. In terms of profitability, EXAS's ROE is -0.09%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, EXAS is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check BDSX's competition here
EXAS vs STIM Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, STIM has a market cap of 89.1M. Regarding current trading prices, EXAS is priced at $104.91, while STIM trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas STIM's P/E ratio is -2.37. In terms of profitability, EXAS's ROE is -0.09%, compared to STIM's ROE of -1.65%. Regarding short-term risk, EXAS is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check STIM's competition here
EXAS vs XGN Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, XGN has a market cap of 87.9M. Regarding current trading prices, EXAS is priced at $104.91, while XGN trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas XGN's P/E ratio is -4.04. In terms of profitability, EXAS's ROE is -0.09%, compared to XGN's ROE of -1.14%. Regarding short-term risk, EXAS is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check XGN's competition here
EXAS vs SERA Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, SERA has a market cap of 65.7M. Regarding current trading prices, EXAS is priced at $104.91, while SERA trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas SERA's P/E ratio is -2.69. In terms of profitability, EXAS's ROE is -0.09%, compared to SERA's ROE of -0.41%. Regarding short-term risk, EXAS is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check SERA's competition here
EXAS vs DRIO Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, DRIO has a market cap of 60.6M. Regarding current trading prices, EXAS is priced at $104.91, while DRIO trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas DRIO's P/E ratio is -0.82. In terms of profitability, EXAS's ROE is -0.09%, compared to DRIO's ROE of +1.18%. Regarding short-term risk, EXAS is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check DRIO's competition here
EXAS vs PRPO Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, PRPO has a market cap of 46.5M. Regarding current trading prices, EXAS is priced at $104.91, while PRPO trades at $26.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas PRPO's P/E ratio is -113.22. In terms of profitability, EXAS's ROE is -0.09%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, EXAS is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check PRPO's competition here
EXAS vs MDXH Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, MDXH has a market cap of 45.9M. Regarding current trading prices, EXAS is priced at $104.91, while MDXH trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas MDXH's P/E ratio is -1.33. In terms of profitability, EXAS's ROE is -0.09%, compared to MDXH's ROE of +5.17%. Regarding short-term risk, EXAS is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check MDXH's competition here
EXAS vs QUCY Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, QUCY has a market cap of 43.7M. Regarding current trading prices, EXAS is priced at $104.91, while QUCY trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas QUCY's P/E ratio is -0.16. In terms of profitability, EXAS's ROE is -0.09%, compared to QUCY's ROE of -4.66%. Regarding short-term risk, EXAS is less volatile compared to QUCY. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check QUCY's competition here
EXAS vs STRR Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, STRR has a market cap of 36M. Regarding current trading prices, EXAS is priced at $104.91, while STRR trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas STRR's P/E ratio is -3.88. In terms of profitability, EXAS's ROE is -0.09%, compared to STRR's ROE of -0.14%. Regarding short-term risk, EXAS is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check STRR's competition here
EXAS vs STRRP Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, STRRP has a market cap of 34.8M. Regarding current trading prices, EXAS is priced at $104.91, while STRRP trades at $10.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas STRRP's P/E ratio is -5.14. In terms of profitability, EXAS's ROE is -0.09%, compared to STRRP's ROE of -0.14%. Regarding short-term risk, EXAS is less volatile compared to STRRP. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check STRRP's competition here
EXAS vs AKU Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, EXAS is priced at $104.91, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas AKU's P/E ratio is -0.13. In terms of profitability, EXAS's ROE is -0.09%, compared to AKU's ROE of -5.32%. Regarding short-term risk, EXAS is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check AKU's competition here
EXAS vs BNR Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BNR has a market cap of 18.5M. Regarding current trading prices, EXAS is priced at $104.91, while BNR trades at $17.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BNR's P/E ratio is -22.88. In terms of profitability, EXAS's ROE is -0.09%, compared to BNR's ROE of -0.10%. Regarding short-term risk, EXAS is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check BNR's competition here
EXAS vs CEMI Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, EXAS is priced at $104.91, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CEMI's P/E ratio is -0.63. In terms of profitability, EXAS's ROE is -0.09%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, EXAS and CEMI have similar daily volatility (0.00).Check CEMI's competition here
EXAS vs ENZ Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, EXAS is priced at $104.91, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas ENZ's P/E ratio is -2.24. In terms of profitability, EXAS's ROE is -0.09%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, EXAS is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check ENZ's competition here
EXAS vs PMD Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, EXAS is priced at $104.91, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas PMD's P/E ratio is -5.24. In terms of profitability, EXAS's ROE is -0.09%, compared to PMD's ROE of -0.32%. Regarding short-term risk, EXAS and PMD have similar daily volatility (0.00).Check PMD's competition here
EXAS vs ME Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, EXAS is priced at $104.91, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas ME's P/E ratio is -0.03. In terms of profitability, EXAS's ROE is -0.09%, compared to ME's ROE of -7.71%. Regarding short-term risk, EXAS and ME have similar daily volatility (0.00).Check ME's competition here
EXAS vs VNRX Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, VNRX has a market cap of 11.1M. Regarding current trading prices, EXAS is priced at $104.91, while VNRX trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas VNRX's P/E ratio is -0.47. In terms of profitability, EXAS's ROE is -0.09%, compared to VNRX's ROE of +0.82%. Regarding short-term risk, EXAS is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check VNRX's competition here
EXAS vs MBAI Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, MBAI has a market cap of 10.4M. Regarding current trading prices, EXAS is priced at $104.91, while MBAI trades at $1.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas MBAI's P/E ratio is 2.68. In terms of profitability, EXAS's ROE is -0.09%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, EXAS is less volatile compared to MBAI. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check MBAI's competition here
EXAS vs NOTV Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, NOTV has a market cap of 10.2M. Regarding current trading prices, EXAS is priced at $104.91, while NOTV trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas NOTV's P/E ratio is -0.12. In terms of profitability, EXAS's ROE is -0.09%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, EXAS is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check NOTV's competition here
EXAS vs CHEK Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CHEK has a market cap of 9.8M. Regarding current trading prices, EXAS is priced at $104.91, while CHEK trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CHEK's P/E ratio is -0.39. In terms of profitability, EXAS's ROE is -0.09%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, EXAS is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check CHEK's competition here
EXAS vs CNTG Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, EXAS is priced at $104.91, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CNTG's P/E ratio is -0.23. In terms of profitability, EXAS's ROE is -0.09%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, EXAS and CNTG have similar daily volatility (0.00).Check CNTG's competition here
EXAS vs BIAF Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BIAF has a market cap of 8.5M. Regarding current trading prices, EXAS is priced at $104.91, while BIAF trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BIAF's P/E ratio is -0.22. In terms of profitability, EXAS's ROE is -0.09%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, EXAS is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check BIAF's competition here
EXAS vs APDN Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, EXAS is priced at $104.91, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas APDN's P/E ratio is -0.10. In terms of profitability, EXAS's ROE is -0.09%, compared to APDN's ROE of -8.97%. Regarding short-term risk, EXAS is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check APDN's competition here
EXAS vs TRIB Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, TRIB has a market cap of 6.1M. Regarding current trading prices, EXAS is priced at $104.91, while TRIB trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas TRIB's P/E ratio is -0.29. In terms of profitability, EXAS's ROE is -0.09%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, EXAS is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check TRIB's competition here
EXAS vs NVTA Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, EXAS is priced at $104.91, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas NVTA's P/E ratio is -0.00. In terms of profitability, EXAS's ROE is -0.09%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, EXAS is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check NVTA's competition here
EXAS vs ADVB Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, ADVB has a market cap of 5.2M. Regarding current trading prices, EXAS is priced at $104.91, while ADVB trades at $4.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas ADVB's P/E ratio is 1.37. In terms of profitability, EXAS's ROE is -0.09%, compared to ADVB's ROE of +0.95%. Regarding short-term risk, EXAS is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check ADVB's competition here
EXAS vs LMDXW Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, EXAS is priced at $104.91, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, EXAS's ROE is -0.09%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, EXAS is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check LMDXW's competition here
EXAS vs LMDX Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, EXAS is priced at $104.91, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas LMDX's P/E ratio is -0.01. In terms of profitability, EXAS's ROE is -0.09%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, EXAS is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check LMDX's competition here
EXAS vs NDRA Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, NDRA has a market cap of 3.8M. Regarding current trading prices, EXAS is priced at $104.91, while NDRA trades at $5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas NDRA's P/E ratio is -0.57. In terms of profitability, EXAS's ROE is -0.09%, compared to NDRA's ROE of -4.97%. Regarding short-term risk, EXAS is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check NDRA's competition here
EXAS vs BNGO Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BNGO has a market cap of 3.8M. Regarding current trading prices, EXAS is priced at $104.91, while BNGO trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BNGO's P/E ratio is -0.24. In terms of profitability, EXAS's ROE is -0.09%, compared to BNGO's ROE of -0.53%. Regarding short-term risk, EXAS is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check BNGO's competition here
EXAS vs BGLC Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BGLC has a market cap of 3.7M. Regarding current trading prices, EXAS is priced at $104.91, while BGLC trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BGLC's P/E ratio is -1.25. In terms of profitability, EXAS's ROE is -0.09%, compared to BGLC's ROE of -0.39%. Regarding short-term risk, EXAS is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check BGLC's competition here
EXAS vs DMTK Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, EXAS is priced at $104.91, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas DMTK's P/E ratio is -0.04. In terms of profitability, EXAS's ROE is -0.09%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, EXAS is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check DMTK's competition here
EXAS vs MYNZ Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, MYNZ has a market cap of 2.9M. Regarding current trading prices, EXAS is priced at $104.91, while MYNZ trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas MYNZ's P/E ratio is -0.13. In terms of profitability, EXAS's ROE is -0.09%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, EXAS is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check MYNZ's competition here
EXAS vs INBS Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, INBS has a market cap of 2.6M. Regarding current trading prices, EXAS is priced at $104.91, while INBS trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas INBS's P/E ratio is -0.28. In terms of profitability, EXAS's ROE is -0.09%, compared to INBS's ROE of -1.74%. Regarding short-term risk, EXAS is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check INBS's competition here
EXAS vs SQL Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, EXAS is priced at $104.91, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas SQL's P/E ratio is -0.40. In terms of profitability, EXAS's ROE is -0.09%, compared to SQL's ROE of +2.74%. Regarding short-term risk, EXAS is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check SQL's competition here
EXAS vs AWH Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, EXAS is priced at $104.91, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas AWH's P/E ratio is -0.09. In terms of profitability, EXAS's ROE is -0.09%, compared to AWH's ROE of +3.65%. Regarding short-term risk, EXAS and AWH have similar daily volatility (0.00).Check AWH's competition here
EXAS vs BIAFW Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BIAFW has a market cap of 1.2M. Regarding current trading prices, EXAS is priced at $104.91, while BIAFW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BIAFW's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to BIAFW's ROE of -3.59%. Regarding short-term risk, EXAS and BIAFW have similar daily volatility (0.00).Check BIAFW's competition here
EXAS vs HTGM Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, EXAS is priced at $104.91, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas HTGM's P/E ratio is -0.03. In terms of profitability, EXAS's ROE is -0.09%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, EXAS and HTGM have similar daily volatility (0.00).Check HTGM's competition here
EXAS vs ISPC Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, ISPC has a market cap of 576.3K. Regarding current trading prices, EXAS is priced at $104.91, while ISPC trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas ISPC's P/E ratio is -0.05. In terms of profitability, EXAS's ROE is -0.09%, compared to ISPC's ROE of -4.96%. Regarding short-term risk, EXAS is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check ISPC's competition here
EXAS vs BIOC Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, EXAS is priced at $104.91, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BIOC's P/E ratio is -0.01. In terms of profitability, EXAS's ROE is -0.09%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, EXAS is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check BIOC's competition here
EXAS vs PRENW Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, PRENW has a market cap of 250.2K. Regarding current trading prices, EXAS is priced at $104.91, while PRENW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas PRENW's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to PRENW's ROE of -0.36%. Regarding short-term risk, EXAS and PRENW have similar daily volatility (0.00).Check PRENW's competition here
EXAS vs SQLLW Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, SQLLW has a market cap of 164.5K. Regarding current trading prices, EXAS is priced at $104.91, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, EXAS's ROE is -0.09%, compared to SQLLW's ROE of +2.74%. Regarding short-term risk, EXAS is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check SQLLW's competition here
EXAS vs TTOO Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, TTOO has a market cap of 22.4K. Regarding current trading prices, EXAS is priced at $104.91, while TTOO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas TTOO's P/E ratio is -0.03. In terms of profitability, EXAS's ROE is -0.09%, compared to TTOO's ROE of +1.47%. Regarding short-term risk, EXAS and TTOO have similar daily volatility (0.00).Check TTOO's competition here
EXAS vs NDRAW Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, EXAS is priced at $104.91, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas NDRAW's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to NDRAW's ROE of -4.97%. Regarding short-term risk, EXAS is less volatile compared to NDRAW. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check NDRAW's competition here
EXAS vs MEUSW Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, EXAS is priced at $104.91, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas MEUSW's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to MEUSW's ROE of -7.71%. Regarding short-term risk, EXAS is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check MEUSW's competition here
EXAS vs OCDX Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, EXAS is priced at $104.91, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas OCDX's P/E ratio is -42.28. In terms of profitability, EXAS's ROE is -0.09%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, EXAS is less volatile compared to OCDX. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check OCDX's competition here
EXAS vs DHR-PA Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, EXAS is priced at $104.91, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, EXAS's ROE is -0.09%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, EXAS is less volatile compared to DHR-PA. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check DHR-PA's competition here
EXAS vs BNGOW Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, EXAS is priced at $104.91, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BNGOW's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to BNGOW's ROE of -0.53%. Regarding short-term risk, EXAS is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check BNGOW's competition here
EXAS vs CHEKZ Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, EXAS is priced at $104.91, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, EXAS is less volatile compared to CHEKZ. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check CHEKZ's competition here
EXAS vs PRXL Comparison May 2026
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, EXAS is priced at $104.91, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas PRXL's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, EXAS is less volatile compared to PRXL. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check PRXL's competition here